Status:
COMPLETED
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
Lead Sponsor:
Avexa
Conditions:
HIV Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
Detailed Description
Lamivudine or emtricitabine are commonly used in combination with other drugs for first-line treatment of HIV infection. Although effective initially, many people later on develop resistance to some o...
Eligibility Criteria
Inclusion
- HIV-1 infected
- M184V mutation in reverse transcriptase
- Currently taking lamivudine
- Viral load \>2000 copies/ml
Exclusion
- Hepatitis B surface antigen positive
- Pregnant or breastfeeding females
- Hepatitis C RNA positive and requiring treatment
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00126880
Start Date
July 1 2005
End Date
January 1 2008
Last Update
June 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Avexa (co-ordinating sites in Australia and Argentina)
Melbourne, Victoria, Australia, 3121